Friday, July 4, 2025 7/4/2025

The Lung EArly Proteins project: A LEAP toward implementing biomarkers in lung cancer screening

Award Number: R01CA262164
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/08/2022
PERIOD OF PERFORMANCE END DATE: 08/31/2027

Group Awards By:

View Award Description

The Lung EArly Proteins project: A LEAP toward implementing biomarkers in lung cancer screening - Summary: The Lung EArly Proteins (LEAP) Project Lung cancer is the most common cause of cancer death worldwide. Screening by low-dose CT can reduce lung cancer mortality among current and former smokers, but the balance of benefits and harms could be improved by leveraging novel tools to optimize decision making. Our objective is to translate a novel panel of protein biomarkers to optimize the decision (1) to initiate screening and (2) to biopsy a nodule. We developed the INTEGRAL panel within the Integrative Analysis of Lung Cancer Risk and Etiology U19 project. We identified proteins to include on the panel by analyzing pre-diagnostic samples collected up to 3 years before diagnosis among over 700 lung cancer case-control pairs in prospective cohort studies. The proteins improved the AUC of a smoking-based model by 0.15, with improvements across histological types. The Lung EArly Proteins (LEAP) project will carry out two late-stage translational studies to evaluate the potential to implement this panel in two key contexts. Aim 1 will determine whether repeated measurements of protein markers over time can better predict development of lung cancer than a single measurement. A repeat-measures model for lung cancer will be developed using blood samples (up to 5 per participant) from 546 lung cancer cases and 546 controls in the Prostate, Lung, and Ovarian Cancer Screening Trial, and independently validated using samples from 539 cases and 539 controls from the Carotene and Retinol Efficacy Trial. We hypothesize that the AUC of the model with repeat measurements will be higher than for a model with a single measurement. Aim 2 will determine whether the protein markers can identify cancers among high-risk screen-detected lung nodules. A biomarker-based prediction model for nodule malignancy will be developed using blood samples from 685 participants (131 cancers) in the Pittsburgh Lung Screening Study, and then validated among 830 participants (213 cancers) in the Multicentric Italian Lung Detection (bioMILD) trial and the St Elizabeth Lung Cancer Screening program. We hypothesize that the AUC of the biomarker model will be higher than for an established, validated nodule malignancy prediction model (the Brock model). The LEAP project will clearly define the contexts in which the INTEGRAL panel is clinical useful. Our mission is to reduce lung cancer mortality by optimizing a proven and effective screening intervention, using novel tools to extend its benefits to all high-risk individuals and reduce screening harms.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $452,301 )
2024	2024	CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER	25 AVE TONY GARNIER	LYON				FRA	Cancer Detection and Diagnosis Research	000	3	8/8/2024	NON-COMPETING CONTINUATION	$452,301
														Subtotal = $452,301

Issue Date FY: 2023 ( Subtotal = $451,746 )
2023	2023	CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER	25 AVE TONY GARNIER	LYON				FRA	Cancer Detection and Diagnosis Research	000	2	8/17/2023	NON-COMPETING CONTINUATION	$451,746
														Subtotal = $451,746

Issue Date FY: 2022 ( Subtotal = $430,982 )
2022	2022	CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER	150 COURS ALBERT THOMAS	LYON				FRA	Cancer Detection and Diagnosis Research	000	1	9/8/2022	NEW	$430,982
														Subtotal = $430,982

Grand Total All Awards = $1,335,029

Top

All Categories

About

Search

Reports

Data Submission

Award Information

The Lung EArly Proteins project: A LEAP toward implementing biomarkers in lung cancer screening

Award Number: R01CA262164

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/08/2022

PERIOD OF PERFORMANCE END DATE: 08/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer